Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: A multicenter, retrospective case series

Journal for ImmunoTherapy of Cancer

Volumn 2, Issue 1, 2014, Pages

  Ravi, Sowmya ^a   Spencer, Kristen ^b   Ruisi, Mary ^c   Ibrahim, Nageatte ^d   Luke, Jason J ^d   Thompson, John A ^e   Shirai, Keisuke ^f   Lawson, David ^g   Bartell, Heddy ^c   Kudchadkar, Ragini ^g   Gunter, Ngoc Thi ^g   Mehnert, Janice M ^b   Lipson, Evan J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis B; Hepatitis C; Ipilimumab; Melanoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; DACARBAZINE; ENTECAVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 2; IPILIMUMAB; NILOTINIB; PREDNISONE; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TENOFOVIR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRONCHOSCOPY; CANCER RADIOTHERAPY; CANCER STAGING; CHOLECYSTECTOMY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATOGRAPHY; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; MELANOMA; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROLOGY; STEREOTACTIC RADIOSURGERY; THROMBOCYTOPENIA; TUMOR GROWTH; VIRUS LOAD; WHOLE BRAIN RADIOTHERAPY;

EID: 84977090790     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-014-0033-1     Document Type: Article

References (21)

1. Maio M, Bondarenko I, Robert C, Thomas L, Garbe C, Testori A, Francis S, Chin K, Wolchok J. Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (ipi) plus dacarbazine (DTIC) on Phase 3 study CA184-024. Ann Oncol 2012, 23:367-367. 10.1093/annonc/mds257.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723. 10.1056/NEJMoa1003466, 20525992.
3. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526. 10.1056/NEJMoa1104621, 21639810.
4. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 62:299-307. 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0, 11055239.
5. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012, 9:156-166. 10.1038/nrclinonc.2012.1, 22271089.
6. Minter S, Willner I, Shirai K. Ipilimumab-induced hepatitis C viral suppression. J Clin Oncol 2013, 31:e307-e308. 10.1200/JCO.2012.46.5831, 23690418.
7. Sharma A, Thompson JA, Repaka A, Mehnert JM. Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. J Clin Oncol 2013, 31:e370-e372. 10.1200/JCO.2012.47.1946, 23775956.
8. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011, 17:6958-6962. 10.1158/1078-0432.CCR-11-1595, 21900389.
9. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012, 30:2691-2697. 10.1200/JCO.2012.41.6750, 22614989.
10. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004, 90:1306-1311. 10.1038/sj.bjc.6601699, 15054446.
11. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, Hou JL, Wen YM, Nanj A, Liang R. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002, 99:2324-2330. 10.1182/blood.V99.7.2324, 11895763.
12. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253. 10.4049/jimmunol.167.3.1245, 11466340.
13. Camara NO, Sebille F, Lechler RI. Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol 2003, 33:3473-3483. 10.1002/eji.200323966, 14635058.
14. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008, 8:523-532. 10.1038/nri2343, 18566595.
15. Stoop JN, van der Molen RG, Baan CC, Van Der L, Luc JW, Kuipers EJ, Kusters JG, Janssen HL. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41:771-778. 10.1002/hep.20649, 15791617.
16. Wherry EJ. T cell exhaustion. Nat Immunol 2011, 12:492-499. 10.1038/ni.2035, 21739672.
17. Sangro B, Gomez-Martin C, De La Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013, 59:81-88. 7, 10.1016/j.jhep.2013.02.022, 23466307.
18. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M, Gostick E, Price DA, Freeman GJ, Wherry EJ, Chang KM. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 2009, 5:e1000313. 10.1371/journal.ppat.1000313, 19247441.
19. Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, Chang KM, Sulkowski M, Marro SO, Anderson J, He B, Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selby M, Korman AJ, Lowy I. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 2013, 8:e63818. 10.1371/journal.pone.0063818, 23717490.
20. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454. 10.1056/NEJMoa1200690, 22658127.
21. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with Lambrolizumab (Anti-PD-1) in Melanoma. N Engl J Med 2013, 369:134-144. 10.1056/NEJMoa1305133, 23724846.